SCHEMBL4835104

SCHEMBL4835104

CCN(C(=O)C(CC(=O)O)CC(=O)NO)c1ccc(-c2ccc(O)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
MMP2 P08253 5/20 0.38
MMP9 P14780 5/20 0.38
MMP8 P22894 5/20 0.38
LTB4R2 Q9NPC1 1/20 0.36
LTA4H P09960 1/20 0.36
MMP1 P03956 3/20 0.35
MMP3 P08254 2/20 0.35
MMP13 P45452 2/20 0.35
MMP14 P50281 2/20 0.35
MMP16 P51512 1/20 0.35
ALDH1A1 P00352 1/20 0.34
GLA P06280 1/20 0.34
TSHR P16473 1/20 0.34
BMP1 P13497 1/20 0.34
MME P08473 1/20 0.34
MLYCD O95822 1/20 0.34
ADAM17 P78536 1/20 0.34
FFAR1 O14842 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4840370 0.91 MMP9 (0.43) MMP2MMP9MMP8LTA4HMMP1
SCHEMBL4840509 0.90 FFAR1 (0.43) HDAC2HDAC8LTA4HMMP3ALDH1A1
SCHEMBL4843156 0.86 MMP3 (0.42) HDAC2MMP2MMP9LTB4R2MMP1
SCHEMBL5891859 0.83 PDE4A (0.41) HDAC2HDAC8ALDH1A1TSHRFFAR1
SCHEMBL6252531 0.82 ALDH1A1 (0.49) MMP2MMP9MMP13MMP14ALDH1A1
SCHEMBL4841415 0.81 HDAC3 (0.39) HDAC2LTA4HMME
SCHEMBL4840468 0.81 MMP3 (0.41) HDAC2HDAC8MMP2MMP9MMP8
SCHEMBL4835871 0.71 SIGMAR1 (0.48) MMP2MMP9MMP8LTA4HALDH1A1
SCHEMBL4841242 0.71 ALDH1A1 (0.38) ALDH1A1GLATSHRMLYCDFFAR1
SCHEMBL4840808 0.71 CA2 (0.35) LTB4R2ALDH1A1GLATSHRMLYCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105539-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-09-12 US claimed
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-06-22 US claimed
EP-1572645-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX Enobia Pharma Inc. (CA) 2005-09-14 EP claimed
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex BIOMEP INC. 2004-09-23 US claimed
WO-2004050620-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX ENOBIA PHARMA (CA) 2004-06-17 WO claimed
US-7365091-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2008-04-29 US disclosed
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2006-12-21 US disclosed
US-7105539-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-09-12 US disclosed
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-06-22 US disclosed
EP-1572645-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX Enobia Pharma Inc. (CA) 2005-09-14 EP disclosed
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex BIOMEP INC. 2004-09-23 US disclosed
WO-2004050620-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX ENOBIA PHARMA (CA) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX GLS, SUCNR1, PGD HDAC2 2340/4885HDAC8 1955/4885MMP2 2325/4885
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, PGD HDAC2 2321/4885HDAC8 2032/4885MMP2 2359/4885
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, GCDH HDAC2 2111/4885HDAC8 1892/4885MMP2 2347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.